We were not able to find an announced earnings date for this symbol yet. Check back again later
Company Info
CEO
Werner Lanthaler
Location
N/A, N/A
Exchange
Nasdaq
Website
https://evotec.com
Summary
Evotec SE operates as drug discovery and development partner for pharmaceutical and biotechnology industry worldwide.
Company Info
CEO
Werner Lanthaler
Location
N/A, N/A
Exchange
Nasdaq
Website
https://evotec.com
Summary
Evotec SE operates as drug discovery and development partner for pharmaceutical and biotechnology industry worldwide.
AI Insights for EVO
5 min read
Quick Summary
Evotec SE is a Germany-based drug discovery and development partner serving pharmaceutical and biotechnology companies worldwide. The company provides research, discovery, preclinical development, and related platform services rather than selling a single finished consumer drug product. Its work spans therapeutic areas including diabetes, fibrosis, infectious diseases, central nervous system diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. Its main customers are large pharmaceutical companies, emerging biotechnology firms, academic institutions, and healthcare innovators that need outsourced research capacity or collaborative development support. The supplied data lists collaboration relationships with Bayer, Lilly, Chinook Therapeutics, Novo Nordisk, Galapagos, Pfizer, and CONBA Pharmaceutical. Evotec trades on Nasdaq as an ADR under the symbol EVO and is classified in the pharmaceutical products industry within the manufacturing sector.
Strengths
•
Evotec's primary strength is its position as a specialized drug discovery and development partner with broad therapeutic reach.
•
The company operates across many disease areas, which reduces dependence on a single drug program or single therapeutic category.
•
Its collaboration history with major pharmaceutical companies such as Bayer, Lilly, Novo Nordisk, Pfizer, and Galapagos provides credibility and potential access to milestone economics.
•
The company has a substantial employee base of about 4,200, suggesting meaningful scientific and operational capacity.
•
Its EV-to-revenue ratio of about 0.1508 and price-to-book value of about 0.7372 may make the stock appear inexpensive if the company can restore sustainable profitability.
Risks
•
Evotec's main weakness is that the company is currently unprofitable based on the supplied financial data.
•
Net income is about negative 121.5 million, total operating income is about negative 65.2 million, and diluted EPS is materially negative.
•
The absence of a dividend and a dividend yield of zero means shareholders are dependent on capital appreciation rather than income.
•
The company may also face margin pressure because outsourced research businesses can require high fixed costs, specialized staff, and continuous investment in technology.
•
The supplied volume moving average is relatively low compared with the previous day's volume, which may indicate limited trading liquidity or occasional volatility in the ADR.
Key Risks
•
The most important risk is continued operating losses, because persistent negative earnings can pressure cash resources, investor confidence, and valuation.
•
Drug discovery is inherently uncertain, and many partnered programs may fail before reaching commercial approval.
•
Customer concentration or dependence on large pharmaceutical collaborations could create volatility if major partners reduce spending, terminate programs, or renegotiate terms.
•
Competition from large global research providers and lower-cost outsourcing markets may pressure pricing and margins.
What to Watch
For the most recent quarter in the supplied dataset, Evotec reported revenue of about 925.2 million and gross profit of about 134.0 million.
The company remained unprofitable, with total operating income of about negative 65.2 million and net income of about negative 121.5 million.
The data does not provide a specific next earnings date, dividend announcement, acquisition, or new Evotec product launch during the quarter.
The collaboration list remains important, with named relationships involving Bayer, Lilly, Novo Nordisk, Galapagos, Pfizer, Chinook Therapeutics, and CONBA Pharmaceutical.
The stock traded within a 52-week range of 1.90 to 4.27, and the previous day volume of 453,779 was well above the listed moving average volume of about 46,516.
The supplied news feed does not appear to contain material Evotec-specific quarter events, because most items reference unrelated companies or products that use the name Evo or Evolution.
Price Drivers
•
Evotec's stock price is likely being driven primarily by profitability concerns, customer demand for outsourced research, collaboration momentum, and investor appetite for biotechnology-related risk.
•
The supplied fundamentals show operating revenue of about 925.2 million, but also a total operating loss of about 65.2 million and net income of about negative 121.5 million.
•
Negative diluted EPS of about negative 1.3614 and a basic EPS of negative 0.28 indicate that earnings are not currently supporting a traditional price-to-earnings valuation.
•
The stock's price-to-book ratio of about 0.7372 suggests the market is valuing the company below stated book value, which may reflect concerns about losses, execution, asset quality, or near-term growth.
•
Beta of 1.313 indicates above-market volatility, so macro risk appetite, interest rates, biotech funding conditions, and broader equity market moves can have an amplified impact.
•
The 52-week range of 1.90 to 4.27 also shows that sentiment can shift sharply around financial results, partnership updates, and any signs of margin improvement.
Recent News
•
The supplied recent news items do not appear to provide material company-specific news about Evotec SE.
•
Several items mention Evolution, Tide evo, an EVO fan-investment platform, Evo cars, Evo cameras, a stablecoin named Evo, and other unrelated products or organizations.
•
These seem to be ticker or keyword matches rather than relevant news about Evotec's drug discovery business.
•
Therefore, the most accurate interpretation is that no clearly relevant Evotec-specific partnership, acquisition, controversy, or product launch is present in the provided news set.
•
Investors should be careful not to confuse Evotec SE with unrelated companies or products that use the term Evo or Evolution.
•
For Evotec, the more relevant updates would be financial results, pharmaceutical collaborations, pipeline progress, cost-control actions, and management commentary.
Market Trends
•
Evotec is affected by the broader trend of pharmaceutical and biotechnology companies outsourcing discovery and development work to specialized partners.
•
Large drugmakers continue to seek external innovation because internal research productivity remains challenging and patent expirations create pressure to replenish pipelines.
•
At the same time, biotechnology funding cycles strongly influence demand from smaller customers, and weak capital markets can reduce early-stage research spending.
•
Artificial intelligence, automation, high-throughput screening, and data-driven biology are reshaping expectations for drug discovery productivity, which creates both opportunity and competitive pressure.
•
The market is also paying closer attention to profitability, cash flow, and balance-sheet discipline, especially for life-science companies with negative earnings.
•
In this environment, Evotec's valuation will likely depend on whether it can convert scientific capabilities and partnerships into sustainable margins and clearer earnings visibility.
AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.
Community Research
Research from investors like you
Be the first to share your analysis on EVO
Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.